ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1369

Impact of SGLT2 Inhibitors and GLP-1 Agonists on RA Flares in Patients on DMARD Therapy: A Retrospective Study
Abstract Number: 1370

Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs for Methotrexate Toxicity
Abstract Number: 1371

Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Abstract Number: 1372

Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Abstract Number: 1373

Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Abstract Number: 1374

AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
Abstract Number: 1375

86-96% of rheumatoid arthritis (RA) patients with RA who have 0 or 1 swollen joint or tender joint but are classified as moderate/high on RA indices have 1-9 comorbidities recognized on a multidimensional health assessment questionnaire (MDHAQ)
Abstract Number: 1376

A Systematic Literature Review on the Economic Burden of Sjögren’s Disease
Abstract Number: 1377

Humanistic Burden of Sjögren’s Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life
Abstract Number: 1378

Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
Abstract Number: 1379

Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Abstract Number: 1380

Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Abstract Number: 1381

Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
Abstract Number: 1382

Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
Abstract Number: 1383

Obesity in Primary Sjogren’s Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].